Dupixent CTCL claims: the FDA safety signal is not the whole story

✓ No fee unless you win✓ Free & confidential review✓ Board-certified trial attorney

Last reviewed: October 1,
2026

If you are looking at a
Dupixent CTCL claim, the
FDA safety signal page is
worth saving. Just do not
treat it like the whole
case.

The FDA's public
table for October through
December 2024 lists
Dupixent (dupilumab)
injection next to one
short phrase:
"Cutaneous T-cell
lymphoma." In the
next column, FDA says it
is "evaluating the
need for regulatory
action."

That is the sentence. Not
a recall. Not a
settlement. Not a ruling
that Dupixent caused a
patient's cancer.

Still, it is not nothing.
A federal regulator
publicly put CTCL on the
watch list for Dupixent.
For families trying to
piece together what
happened after months or
years of rash visits,
injections, biopsies, and
finally a lymphoma
diagnosis, that can be an
important document to keep
in the file.

Our broader case overview
is here:Dupixent lawsuit hub. This page is narrower.
It is about what the FDA
signal can do for a
records review, and what
it cannot do.

Read the FDA signal
carefully

A safety signal is a lead.
FDA uses these reports
when it is looking at
possible new safety
information. Sometimes the
review leads to a label
change. Sometimes it leads
nowhere public. Sometimes
it sits in the
uncomfortable middle for a
while.

That is why the wording
matters. FDA did not say
"Dupixent causes
CTCL." It said the
issue was under review for
possible regulatory
action.

For a potential claimant,
that difference is not a
technicality. Lawyers
still have to connect the
person's own history
to the alleged warning
problem. Doctors still
have to handle the medical
questions. The FDA line
can help show why CTCL is
being discussed, but it
does not diagnose anyone
and it does not prove an
individual lawsuit.

Why the warning issue is
front and center

The current Dupixent
prescribing information is
one reason plaintiffs are
focused on warnings. The
label lists approved uses,
dosing, contraindications,
and warnings. It is the
starting point for what
doctors and patients were
told through official
prescribing materials.

The lawsuits allege
Sanofi, Regeneron, and
related entities failed to
warn about CTCL concerns.
Some complaints use
different language from
case to case: caused,
accelerated, unmasked, or
delayed diagnosis. Those
words can sound similar in
an advertisement. In a
legal review, they are
very different.

A person who already had
early CTCL mistaken for
eczema is not the same
fact pattern as a person
alleging a new cancer
after treatment. A person
with mycosis fungoides
confirmed by biopsy is not
the same as a person with
a different lymphoma. The
records have to sort that
out.

Please do not change a
prescription because of a
lawsuit article. If the
rash is changing,
spreading, or not behaving
like the condition you
were told you had, talk to
the prescribing doctor or
a dermatologist about what
testing makes sense.

What the JPML order says
the MDL will fight about

MDL No. 3180 was created
on June 4, 2026. The
federal cases were sent to
the District of New Jersey
before Judge Zahid N.
Quraishi.

The JPML transfer order is
useful because it
describes the common
questions. The panel wrote
that the cases involve
issues such as whether
scientific literature
shows a causal link
between Dupixent use and
CTCL, when the defendants
should have learned about
any link, and whether
warnings were adequate.

That is the overlap with
the FDA signal. The
regulator is reviewing a
safety issue. The MDL is
where plaintiffs and
defendants will fight over
science, company
knowledge, and warnings.

At the time of transfer,
the JPML listed 15 actions
and seven potential
tag-along actions. Case
counts may rise or fall.
Do not build your
understanding around a
number on a given day.
Build it around the facts
that can be documented.

For background on active
matters we are tracking,
see thecurrent mass torts page. For attorney-review
background, seeAbout Mass Tort America.

The file to build before
memories get fuzzy

The best first step is
boring: get the records.

Start with the drug
history. Save pharmacy
records,
specialty pharmacy
shipments, injection
dates, dose changes, and
the stop date. If you do
not know the exact first
injection date, write down
the month and year and
mark it as approximate.

Then pull the skin
records. Dermatology notes
from before Dupixent can
be just as important as
notes from after it
started. Early CTCL can
look like eczema. The
chart may show whether the
rash was adult-onset,
stubborn, changing, or
repeatedly biopsied.

The biopsy and pathology
reports matter most. Look
for words such as CTCL,
mycosis fungoides, Sezary
syndrome, atypical
lymphoid infiltrate,
T-cell clonality,
immunohistochemistry, or
flow cytometry. Oncology
notes can help show
staging, treatment, and
follow-up.

Portal messages and dated
photos can help when they
already exist. Do not
stage new photos to
recreate old symptoms. A
plain timeline is usually
better: symptoms, Dupixent
start, changes, biopsy,
diagnosis.

Do not stretch the
diagnosis

The JPML order focuses on
CTCL and CTCL subtypes. It
did not decide that every
lymphoma belongs in MDL
3180. It also treated
B-cell lymphoma, Hodgkin
lymphoma, and diseases
that are not T-cell
lymphomas as different
issues.

That matters for families
because a broad word like
"lymphoma" can
hide a lot of medical
detail. A case review
needs the exact diagnosis,
not a shortened version
remembered from a phone
call.

There is also no announced
settlement fund. No
bellwether trial has
resolved these
allegations. No court has
made a final ruling that
Dupixent caused CTCL in
any person.

The FDA signal is a real
source. It belongs in the
file. It just cannot carry
the file by itself.

Common questions we hear

People usually ask four
things. First, no, the FDA
safety signal is not a
final finding that
Dupixent causes CTCL.
Second, CTCL is not simply
bad eczema, although early
CTCL can look like eczema.
Third, the diagnoses most
closely tied to MDL 3180
are CTCL and CTCL subtypes
such as mycosis fungoides
and Sezary syndrome.
Fourth, the safest first
records to save are the
prescription history,
dermatology chart, biopsy
or pathology reports,
oncology records, and
dated portal messages or
photos that already exist.

None of that should change
medical care on its own. A
prescribing doctor should
guide medication
decisions.

Sources

This article is attorney
advertising and is for
informational purposes
only. It is not medical
advice and does not create
an attorney-client
relationship. Prior
results do not guarantee a
similar outcome.
Submitting information for
review does not create an
attorney-client
relationship.

Robert B. Baker, Board-Certified Civil Trial Attorney
Claims reviewed by Baker Legal Team
Robert B. Baker, Esq., B.C.S. — Board-Certified Civil Trial Lawyer. 30+ years of trial experience, more than $400 million recovered for clients. About Robert Baker →

This litigation is not currently accepting new clients. Explore active litigation you may qualify for.

Attorney Advertising. Prior results do not guarantee a similar outcome. Submitting a form does not create an attorney client relationship.